ProMIS Neurosciences (NASDAQ:PMN – Get Free Report) issued its earnings results on Monday. The company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.12, Zacks reports.
ProMIS Neurosciences Price Performance
Shares of NASDAQ:PMN traded up $0.04 during trading on Tuesday, reaching $0.73. The stock had a trading volume of 73,038 shares, compared to its average volume of 70,651. The stock has a market capitalization of $23.93 million, a PE ratio of -7.32 and a beta of 0.58. The business’s 50-day moving average price is $0.82 and its 200 day moving average price is $0.96. ProMIS Neurosciences has a 52 week low of $0.62 and a 52 week high of $2.61.
Analyst Upgrades and Downgrades
Separately, Guggenheim restated a “buy” rating and set a $6.00 price target on shares of ProMIS Neurosciences in a report on Tuesday.
ProMIS Neurosciences Company Profile
ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
See Also
- Five stocks we like better than ProMIS Neurosciences
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy
- Profitably Trade Stocks at 52-Week Highs
- Amazon Falls Back to a Key Support Line: Here’s How to Play It
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Buffett Trims Equities, But Still Keeps Buying This Stock
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
